MNKD
MannKind Corporation
$4.04
-0.05
(-1.22%)
Mkt Cap
1.25B
Volume
3,155,743
52W Range
2.23-6.51
Sector
Healthcare
Beta
1.09
EPS (TTM)
-0.08
P/E Ratio
283.50
Revenue (TTM)
360.78M
Rev Growth (5Y)
+39.9%
EPS Growth (5Y)
-37.5%
AlphaVal · Fair Value
What we estimate one share is worth
$8.00
Undervalued
strong signal
49.5% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
High-Growth Software
30.0 / 100 pillar composite (overridden)
Fast-growing software, still scaling up — graded A–F vs. similar companies.
Company Description
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 348.97M | 285.50M | 198.96M | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M | 11.74M | 174.76M | 0 | 0 |
| Net Income | 5.86M | 27.59M | (11.94M) | (87.40M) | (80.93M) | (57.24M) | (51.90M) | (86.97M) | (117.33M) | 125.66M | (368.44M) | (198.38M) |
| EPS | 0.02 | 0.10 | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.37 | -4.54 | -2.57 |
| Free Cash Flow | 13.69M | 32.82M | (8.35M) | (88.29M) | (73.17M) | (32.91M) | (91.05M) | (38.09M) | (64.78M) | (79.23M) | (67.52M) | (20.01M) |
| FCF / Share | 0.04 | 0.12 | -0.03 | -0.34 | -0.29 | -0.15 | -0.47 | -0.26 | -0.62 | -0.86 | -0.83 | -0.26 |
| Operating CF | 18.25M | 42.51M | 34.09M | (80.70M) | (61.71M) | (28.13M) | (88.48M) | (37.73M) | (64.78M) | (78.09M) | (57.23M) | 4.09M |
| Total Assets | 792.18M | 393.84M | 475.20M | 295.28M | 321.16M | 108.61M | 93.72M | 107.70M | 84.58M | 107.06M | 126.41M | 394.44M |
| Total Debt | 473.38M | 47.70M | 272.62M | 288.40M | 289.22M | 123.44M | 121.41M | 102.49M | 156.82M | 148.50M | 139.50M | 49.52M |
| Cash & Equiv | 74.88M | 46.34M | 238.48M | 69.77M | 124.18M | 67.00M | 29.91M | 71.16M | 43.95M | 22.89M | 59.07M | 120.84M |
| Book Value | (51.02M) | (78.82M) | (246.17M) | (250.54M) | (209.35M) | (180.42M) | (190.53M) | (175.08M) | (214.73M) | (183.59M) | (350.33M) | (73.77M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.17M | 111.95M | 82.13M | 76.53M | 78.35M | 76.78M | 70.08M | 72.39M | 66.26M | 58.47M | 51.25M | 48.61M |
| Net Income | (16.62M) | (15.95M) | 7.99M | 668,000 | 13.16M | 7.42M | 11.55M | (2.01M) | 10.63M | 1.40M | 1.72M | (5.26M) |
| EPS | -0.05 | -0.05 | 0.03 | 0.00 | 0.04 | 0.03 | 0.04 | -0.01 | 0.04 | 0.01 | 0.01 | -0.02 |
| Free Cash Flow | (7.52M) | (9.95M) | 22.36M | 7.83M | (6.71M) | 19.75M | 7.91M | 861,000 | 4.29M | 15.80M | (2.72M) | (14.27M) |
| FCF / Share | -0.02 | -0.03 | 0.07 | 0.03 | -0.02 | 0.07 | 0.03 | 0.00 | 0.02 | 0.06 | -0.01 | -0.05 |
| Operating CF | (5.64M) | (7.96M) | 23.49M | 8.95M | (6.38M) | 22.64M | 9.33M | 3.83M | 6.70M | 21.68M | 8.66M | 2.60M |
| Total Assets | 744.40M | 792.18M | 494.64M | 411.70M | 410.14M | 393.84M | 464.20M | 443.84M | 480.88M | 475.20M | 320.33M | 313.42M |
| Total Debt | 436.67M | 473.38M | 225.95M | 46.82M | 47.25M | 157.22M | 240.28M | 231.03M | 267.79M | 272.62M | 277.53M | 279.08M |
| Cash & Equiv | 52.83M | 74.88M | 127.39M | 57.01M | 47.31M | 46.34M | 62.37M | 96.64M | 193.27M | 238.48M | 83.02M | 86.18M |
| Book Value | (59.20M) | (51.02M) | (44.55M) | (55.04M) | (58.62M) | (78.82M) | (209.93M) | (225.78M) | (229.97M) | (246.17M) | (251.78M) | (260.49M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MNKD News
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
US FDA approves MannKind's inhaled insulin for children